NIOVF, OTC #Phase 1 Plato Gold Reports on Final Results of Phase I Exploration Program for the Pic River PGE-Cu Project February 23, 2023 07:15 EST Toronto, Feb. 23, 2023 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) is pleased to report the final results from its Phase 1 exploration program completed in November 2022 on the Pic River PGE-Cu Project. The property is located 30 km northwest No Comments
AVIR, NASDAQ #Phase 1 Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023 February 23, 2023 07:00 EST Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studies suggest a favorable drug-drug interaction profile. No dosage adjustment No Comments
OTC, SKYE #Cannabis #Phase 1 #Positive Clinical Trial Results Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study February 23, 2023 07:00 EST San Diego, California–(Newsfile Corp. – February 23, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received a positive recommendation following a pre-specified data review by the safety review committee (“SRC”) based on dosing No Comments
DARE, NASDAQ #Phase 1 Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1 February 22, 2023 08:00 EST SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical ingredient diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), No Comments
IMCR, NASDAQ #Cancer #New Clinical Trial Data #Phase 1 Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV February 22, 2023 07:00 EST Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial shows IMC-M113V is well tolerated Expected markers of T cell activation observed in half of participants at No Comments
AMEX, PHGE #Phase 1 #Positive Clinical Trial Results #Trending News BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis February 22, 2023 06:30 EST BX004 therapy safe and well-tolerated across all patients and dose levels Preliminary signals of efficacy also observed, with notable reductions in bacterial burden Dosing in patients in Part 2 initiated, results expected in Q3 23 Company to host webcast/cc to discuss Part 1 data today at 9:00 am ET No Comments
KNTE, NASDAQ #New Clinical Trial Data #Phase 1 #Production Expansion #Trending News Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People’s Republic of China February 21, 2023 16:05 EST Kinnate to retain Kinnjiu’s cash, intellectual property and other assets, including key personnel and legal entity structure Kinnate’s cash runway still expected to fund current operations into mid-2024 Trial sites open in People’s Republic of China (PRC) and Taiwan for ongoing Phase 1 clinical trial evaluating exarafenib, a pan-RAF No Comments
ALRN, NASDAQ #Cancer #Phase 1 #Trending News Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives February 21, 2023 08:30 EST BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint No Comments
NYSE, TOVX #Phase 1 #Trending News Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients February 16, 2023 12:05 EST – Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – – Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with HCT and was not observed in blood samples from the majority of the evaluable patients – ROCKVILLE, Md., Feb. No Comments
AGNPF, OTC #Letter to Shareholders #New Clinical Trial Data #Phase 1 Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase February 16, 2023 07:02 EST VANCOUVER, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its No Comments
Tactile Systems Technology, Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock 02/23/2023
Columbia Banking System Set to Join S&P MidCap 400; Verra Mobility to Join S&P SmallCap 600 02/23/2023